Innocan Pharma plans NYSE American listing around January 30

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced it anticipates listing on NYSE American on or around January 30, 2026, subject to approval of its listing application and continued compliance with exchange rules.

The pharmaceutical technology company, which focuses on developing drug delivery platform technologies, is conducting a concurrent securities offering in connection with the anticipated NYSE listing, subject to market conditions and regulatory approval. Additional details regarding the offering will be provided through filings with the Securities and Exchange Commission and SEDAR+.

Innocan expects its common shares will continue trading on the OTC Markets' OTCQB until market close on or about January 29, 2026. Upon effectiveness of the NYSE American listing, OTCQB trading will terminate. The company's shares will continue trading on the Canadian Securities Exchange under the symbol "INNO."

Stockholders do not need to take any action prior to the NYSE American listing, according to the company's statement.

Innocan operates in pharmaceuticals and wellness sectors. In pharmaceuticals, the company developed a CBD-loaded liposome drug delivery platform for synthetic CBD pain management. In wellness, it develops self-care and beauty products through its 60% owned subsidiary, BI Sky Global Ltd.

The company is based in Herzliya, Israel, and Calgary, Alberta.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Phathom completes enrollment in Phase 2 EoE trial of Voquezna
• Silexion gets German approval for pancreatic cancer trial of SIL204